GlassScriptPhysician profile
Daniel S Christensen
NPI 1306288444
$8,431.13
in general payments reported to CMS, 2019-2025
15 companies · $692 in 2025
The $692 reported for 2025 was more than what 82% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,715 · 2022: $974 · 2023: $2,050 · 2024: $3,000 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,447 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,165 · Consulting Fee: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,446.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,164.99 |
| Consulting Fee | $130.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,266.29 | 2021-2025 | Ams 700, General - Erectile Dysfunction, Ams 800 Artificial Urinary Sphincter |
| Medtronic, INC. | $1,849.58 | 2023-2025 | Interstim, Nuro |
| Endo Pharmaceuticals INC. | $1,842.49 | 2021-2024 | Xiaflex, Aveed |
| Antares Pharma, INC. | $490.25 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Endo USA, INC. | $421.23 | 2024-2025 | Xiaflex |
| Janssen Biotech, INC. | $393.27 | 2024-2025 | Erleada |
| Axonics, INC. | $289.21 | 2022-2023 | Axonics |
| Sumitomo Pharma America, INC. | $230.21 | 2023-2025 | Gemtesa, Orgovyx |
| Acerus Pharmaceuticals Corporation | $134.32 | 2022-2023 | Natesto |
| Novo Nordisk INC | $124.99 | 2023 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $124.71 | 2022 | |
| Tolmar, INC. | $99.61 | 2023-2025 | Jatenzo |
| Coloplast Corp | $86.11 | 2023 | Titan |
| Halozyme INC | $46.43 | 2023 | |
| Urovant Sciences INC | $32.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Christensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.